Journal of Nutraceutical Science and Innovation

Now Accepting Manuscripts Annual (One issue per year) Open Access Single-Blind Peer Review
Editorial & Review Timeline
3 - 4 Days Initial Quality Review
20 Days Peer Evaluation Summary
30 - 45 Days Complete Editorial Processing Time

Prof Ralf Weiskirchen

Ph.D

  • Affiliation: RWTH University Hospital Aachen, Germany
  • Department: Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry IFMPEGKC
  • University: RWTH Aachen University
  • Email: rweiskirchen@ukaachen.de
  • Country: Germany

Professor Dr. Ralf Weiskirchen is a full professor and Head of the Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC) at RWTH University Aachen, Germany. He obtained his PhD from the Institute of Biochemistry, Medical Faculty, University of Cologne, in 1994. He has extensive research experience in molecular biology, microbiology, biochemistry, pharmacology and genetics. His major research focuses on the molecular mechanisms underlying hepatic diseases, including liver inflammation, fibrosis, cirrhosis and hepatocellular carcinoma. His research also encompasses cytokine and chemokine activities, biomarkers, metabolic disorders, lipid metabolism and therapeutic strategies. Professor Weiskirchen has authored more than 390 original research articles, numerous reviews, editorials and book chapters and has supervised numerous PhD and MD researchers. He has extensive editorial and peer-review experience across international journals in pharmacology, nutrition, metabolism, molecular biology and biomedical sciences. He has also been recognized among the Clarivate Highly Cited Researchers in 2024, 2025 and 2026.

Professor Dr. Ralf Weiskirchen has extensive scientific, academic and editorial experience. He has served as Head/Director of the Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry at RWTH University Aachen since 2014. He has supervised 26 PhD students, 24 MD students and 2 dentists and has served as reviewer/chairman for approximately 280 PhD/MD examinations. He is involved in numerous international editorial and scientific activities, including Editorial Board Member of Food, Nutrition and Health and British Journal of Pharmacology; Associate Editor for Frontiers in Drug Delivery, Frontiers in Cellular and Infection Microbiology, Livers and other journals; Executive Editor of Journal of Cell Communication and Signaling; and Editor-in-Chief of Fibrosis and Homestatic Medicine. He has also served as a Guest Editor and Topic Editor for several international journals in nutrition, pharmacology, immunology and biomedical sciences. He is an experienced peer reviewer for numerous international journals and funding agencies. He has authored 392 original articles, 345 reviews/editorials and 52 book chapters, with an h-index of 77 as of September 2026. He has been included in the Clarivate Highly Cited Researchers lists for 2024, 2025 and 2026.

  • Meurer SK, Bronneberg G, Penners C, Kauffmann M, Braunschweig T, Liedtke C, Huber M, Weiskirchen R. (2025). TGF-β1 induces mucosal mast cell genes and is negatively regulated by the IL-3/ERK1/2 axis. Cell Communication and Signaling, 23(1):76.
  • Leopold M, Mass-Sanchez PB, Krizanac M, et al., Weiskirchen R. (2025). How the liver transcriptome and lipid composition influence the progression of nonalcoholic fatty liver disease to hepatocellular carcinoma in a murine model. Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, 1870(1):159574.
  • Mass-Sanchez PB, Krizanac M, Štancl P, et al., Weiskirchen R, Asimakopoulos A. (2024). Perilipin 5 deletion protects against nonalcoholic fatty liver disease and hepatocellular carcinoma by modulating lipid metabolism and inflammatory responses. Cell Death Discovery, 10(1):94.
  • Chaudhary R, Goodman LS, Wang S, et al., Weiskirchen R, et al. (2024). Cholesterol modulates type I/II TGF-β receptor complexes and alters the balance between Smad and Akt signaling in hepatocytes. Communications Biology, 7(1):8.
  • Weiskirchen R. (2023). Targeting copper to combat macrophage-driven inflammation: A potential advanced therapeutic strategy. Signal Transduction and Targeted Therapy, 8(1):339.
  • Borkham-Kamphorst E, Meurer SK, Weiskirchen R. (2023). Expression and biological function of the cellular communication network factor 5 (CCN5) in primary liver cells. Journal of Cell Communication and Signaling, 17(2):307-320.
  • Vucur M, Ghallab A, Schneider AT, et al., Weiskirchen R, et al. (2023). Sublethal necroptosis signaling promotes inflammation and liver cancer. Immunity, 56(7):1578-1595.e8.
  • Otto J, Verwaayen A, Penners C, et al., Weiskirchen R, et al. (2023). Expression of Cyclin E1 in hepatic stellate cells is critical for the induction and progression of liver fibrosis and hepatocellular carcinoma in mice. Cell Death & Disease, 14(8):549.
  • Krizanac M, Mass Sanchez PB, Schröder SK, Weiskirchen R, Asimakopoulos A. (2023). Lipid-independent regulation of PLIN5 via IL-6 through the JAK/STAT3 axis in Hep3B cells. International Journal of Molecular Sciences, 24(8):7219.